Cover Image
Market Research Report

Advances in Monoclonal Antibody Therapeutics

Published by Frost & Sullivan Product code 340911
Published Content info 94 Pages
Delivery time: 1-2 business days
Price
Back to Top
Advances in Monoclonal Antibody Therapeutics
Published: September 29, 2015 Content info: 94 Pages
Description

Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.

Table of Contents
Product Code: D65E-01-00-00-00

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Research Scope
  • 2. Research Methodology
  • 3. Key Findings

2. MONOCLONAL ANTIBODIESA SNEAK PREVIEW

Monoclonal AntibodiesA Sneak Preview

  • 1. Technology Snapshot - Multiple Segmentation
  • 2. Industry Overview - Main Innovations
  • 3. Industry Overview - Main Innovators
  • 4. Technology Roadmap Toward Precision Medicine

3. STRATEGIC ASSESSMENT OF THE INDUSTRY ENVIRONMENT

Strategic Assessment of the Industry Environment

  • 1. Therapeutic Areas and Clinical Indications
  • 2. Molecular Agents and Cell Targets
  • 3. Developmental Stage Focus
  • 4. Market Potential
  • 5. Market Evolution
  • 6. Venture Capital Investment
  • 7. Company Stage Investment Focus
  • 8. Government Funding and Support
  • 9. Worldwide Landscape
  • 10. Key Drivers and Restraints
  • 11. Key Technical and Business Challenges

4. INDUSTRY BEST PRACTICES AND STRATEGIC INSIGHTS

Industry Best Practices and Strategic Insights

  • 1. Industry Assessment - Partnerships and Alliances
  • 2. Stakeholder Assessment for Partnerships
  • 3. Partnerships and Alliances Models
  • 4. Partnerships and Collaborations
  • 5. Partnerships and Collaborations (continued)
  • 6. Partnerships and Collaborations (continued)
  • 7. Patent Analysis
  • 8. Patent publishing trends
  • 9. Patent office-wise distribution

5. STRATEGIC EVALUATION OF R&D PORTFOLIO

Strategic Evaluation of R&D Portfolio

  • 1. R&D Success and Key Performance Indicators
  • 2. Analytical Hierarchy Process (AHP)
  • 3. Analytical Hierarchy Process (AHP)
  • 4. Analytical Hierarchy Process (AHP)
  • 5. Analytical Hierarchy Process (AHP)
  • 6. Analytical Hierarchy Process (AHP)
  • 7. Analytical Hierarchy Process (AHP)
  • 8. Analytical Hierarchy Process (AHP)
  • 9. Analytical Hierarchy Process (AHP)
  • 10. Analytical Hierarchy Process (AHP)

6. KEY CONTACTS

Key Contacts

  • 1. Contacts
  • 2. Contacts (continued)

7. APPENDIX

Appendix

  • 1. Strategic R&D Pipeline - The Road Ahead
  • 2. R&D Pipeline Assessment
  • 3. R&D Pipeline Assessment (continued)
  • 4. R&D Pipeline Assessment (continued)
  • 5. R&D Pipeline Assessment (continued)
  • 6. R&D Pipeline Assessment (continued)
  • 7. R&D Pipeline Assessment (continued)
  • 8. R&D Pipeline Assessment (continued)
  • 9. R&D Pipeline Assessment (continued)
  • 10. R&D Pipeline Assessment (continued)
  • 11. R&D Pipeline Assessment (continued)
  • 12. R&D Pipeline Assessment (continued)
  • 13. R&D Pipeline Assessment (continued)
  • 14. R&D Pipeline Assessment (continued)
  • 15. R&D Pipeline Assessment (continued)
  • 16. R&D Pipeline Assessment (continued)
  • 17. R&D Pipeline Assessment (continued)
  • 18. R&D Pipeline Assessment (continued)
  • 19. R&D Pipeline Assessment (continued)
  • 20. R&D Pipeline Assessment (continued)
  • 21. R&D Pipeline Assessment (continued)
  • 22. R&D Pipeline Assessment (continued)
  • 23. R&D Pipeline Assessment (continued)
  • 24. R&D Pipeline Assessment (continued)
  • 25. R&D Pipeline Assessment (continued)
  • 26. R&D Pipeline Assessment (continued)
  • 27. Product Line Assessment
  • 28. Product Line Assessment (continued)
  • 29. Product Line Assessment (continued)
  • 30. Product Line Assessment (continued)
  • 31. Product Line Assessment (continued)
  • 32. Product Line Assessment (continued)
  • 33. Product Line Assessment (continued)
  • 34. Product Line Assessment (continued)
  • 35. Product Line Assessment (continued)
  • 36. Product Line Assessment (continued)
  • 37. Abbreviations
  • 38. Legal Disclaimer
Back to Top